The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring following therapy.
 
Maria Velez Velez
Consulting or Advisory Role - AstraZeneca
 
Elliot Kang
No Relationships to Disclose
 
Chester Thompson
No Relationships to Disclose
 
Collin Shen
No Relationships to Disclose
 
Seung Jun Park
No Relationships to Disclose
 
Andy Han
No Relationships to Disclose
 
Jackson Lind-Lebuffe
No Relationships to Disclose
 
Arjan Gower
Consulting or Advisory Role - HMP
 
Daniel Li
No Relationships to Disclose
 
Philippe Rochigneux
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation (Inst); Novartis (Inst); Roche; Viatris
Research Funding - AstraZeneca (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Tristan Grogan
No Relationships to Disclose
 
David Elashoff
No Relationships to Disclose
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Atreca; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Hexagon; Hookipa Biotech; I-Mab; ITeos Therapeutics; LianBio; Lilly; Merck; Merus; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Sanofi; Seagan; Strata Oncology; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Aaron Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Nordics; G1 Therapeutics; Gilead Sciences; IQVIA; Janssen Oncology; Jazz Pharmaceuticals; Leica Biosystems; Lilly; Molecular Axiom; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; Duality Biologics; eFFECTOR Therapeutics; WindMIL
Patents, Royalties, Other Intellectual Property - Pending Patents U.S. Provisional Patent Application No. 63/527,899